MedTrace Logo

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

NCT01661790 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-03-25

Study results available
· View outcomes & findings →

Summary

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Conditions

  • Malignant Pleural Effusion

Interventions

DRUG

Bevacizumab

Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week

DRUG

Cisplatin

Cisplatin 30mg,intrapleural administration,each 2 week

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Nan Du · PLA 304 hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-06-30
Completion
2012-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01661790 on ClinicalTrials.gov